Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 24 of the 199 sources its claims cite were checked for support.
Abstract
Chronic glucocorticoid (GC) treatment represents a widely-prescribed therapy for several diseases in consideration of both anti-inflammatory and immunosuppressive activity but, if used at high doses for prolonged periods, it can determine the systemic effects characteristic of Cushing’s syndrome. In addition to signs and symptoms of hypercortisolism, patients on chronic GC therapy are at risk to develop tertiary adrenal insufficiency after the reduction or the withdrawal of corticosteroids or during acute stress. This effect is mediated by the negative feedback loop on the hypothalamus-pituitary-adrenal (HPA) axis, which mainly involves corticotropin-release hormone (CRH), which represents the most important driver of adrenocorticotropic hormone (ACTH) release. In fact, after withdrawal of chronic GC treatment, reactivation of CRH secretion is a necessary prerequisite for the recovery of the HPA axis. In addition to the well-known factors which regulate the degree of inhibition of the HPA during synthetic GC therapy (type of compound, method of administration, cumulative dose, duration of the treatment, concomitant drugs which can increase the bioavailability of GCs), there is a considerable variation in individual physiology, probably related to different genetic profiles which regulate GC receptor activity. This may represent an interesting basis for possible future research fields.
Overview
CoChat Summary
TL;DR
Chronic synthetic glucocorticoid therapy can suppress the hypothalamus-pituitary-adrenal (HPA) axis and cause tertiary adrenal insufficiency, especially after dose reduction or withdrawal. Risk is shaped by compound, route, dose, duration, drug interactions, and individual genetic variation, while incidence estimates remain uncertain because diagnostic criteria vary.
Key findings
- Chronic glucocorticoids inhibit CRH and ACTH; after withdrawal, reactivation of CRH secretion is a necessary prerequisite for HPA axis recovery. A cited systematic review found hypoadrenalism persisted in 15% of patients retested three years after glucocorticoid withdrawal.
- Exposure is common: in 2008 almost 1% of the UK adult population were exposed to oral glucocorticoids, including 0.79% on long-term courses longer than three months. About 6% of hospitalized patients may have glucocorticoid-induced adrenal insufficiency, and prevalence estimates from large observational studies range from 14–63%.
- Adrenal crisis incidence was reported as 15.1/100 patient-years in tertiary adrenal insufficiency, compared with 5.2/100 patient-years in primary and 3.6/100 patient-years in secondary adrenal insufficiency. Infections were the most important precipitant, and about 30% of tertiary adrenal insufficiency crises occurred after glucocorticoid dose reduction.
- Risk predictors include prednisone >20 mg/day for >3 weeks making HPA suppression “likely,” evening/bedtime prednisone ≥5 mg for more than a few weeks also increasing risk, and 10–20 mg/day for >3 weeks being intermediate risk. Hydrocortisone and cortisone acetate are least suppressive; dexamethasone is the most potent ACTH suppressor.
Methods
- Narrative review evaluating the physiopathology and clinical effects of synthetic glucocorticoids on HPA function.
- Synthesizes literature on normal HPA physiology, synthetic glucocorticoid pharmacology, receptor biology, clinical adrenal insufficiency, and genetic variability, including cited systematic reviews, observational studies, animal models, and in vitro assays.
- No primary data collection or systematic search strategy is reported.
Limitations
- The paper states that a clear incidence of glucocorticoid-induced adrenal insufficiency cannot be assessed because of substantial differences in diagnostic criteria and variability in tests, including standard- and low-dose ACTH tests, insulin tolerance tests, and CRH stimulation, with different cut-offs and sensitivity/specificity.
- The paper notes that in vitro receptor transactivation systems differ from in vivo conditions, including steroid-metabolizing enzymes and heat shock protein concentrations, and that the literature on rapid glucocorticoid feedback is confusing and limited by not considering endogenous cortisol pulses.
- Evident from the text: as a narrative review, it does not describe a systematic search or formal quality appraisal, and many clinical estimates rely on heterogeneous cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Daily cortisol rhythm in healthy volunteers [23].](https://figures.cochat.ai/paper-figures/92ea4fe5961f4d21bab3c5ba7f3fae55/treatment-with-synthetic-glucocorticoids-and-the-hypothalamus-pituitary-adrenal-figure-1.jpg)
![Figure 2 Corticotropin-release hormone (CRH) knock-out (KO) mouse model in regulation of hypothalamus-pituitary-adrenal (HPA) axis [59]. In CRH KO models proopiomelanocortin (POMC) mRNA, but not plasmatic adrenocorticotropic hormone (ACTH), rises after adrenalectomy. Glucocorticoids, but not mineralocorticoids (blue dotted arrow) reduce POMC increase induced by adrenalectomy. CRH administration restores a significant ACTH secretion.](https://figures.cochat.ai/paper-figures/3b5ea56302d54169a79ca7a76715b45c/treatment-with-synthetic-glucocorticoids-and-the-hypothalamus-pituitary-adrenal-figure-2.jpg)
![Figure 3 Tissue side effects of synthetic glucocorticoids [1].](https://figures.cochat.ai/paper-figures/eacadeabe8df4e1faa6debafaceafd95/treatment-with-synthetic-glucocorticoids-and-the-hypothalamus-pituitary-adrenal-figure-3.jpg)
Verification
Claims the paper makes
24 Valid · 2 Not valid · 161 Not checked · 24 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“their therapeutic actions are counterbalanced by adverse side effects associated with high doses and long-term use, such as osteoporosis, skin atrophy, diabetes, hypertension, abdominal obesity, acne, infection, and growth retardation [8], as well as ocular hypertension [9].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 1. Introduction
What the sources say
- Not checked yetcites [8] Schacke H. Docke W.D. Asadullah K. Mechanisms involved in the side effects of glucocorticoids Pharmacol. Ther. 2002 96 23 43 10.1016/S0163-7258(02)00297-8 12441176 source
- Supportedcites [9] Dibas A. Yorio T. Glucocorticoid therapy and ocular hypertension Eur. J. Pharmacol. 2016 787 57 71 10.1016/j.ejphar.2016.06.018 27388141 PMC5014726 source
The citation [9] is attached specifically to the 'ocular hypertension' element of the citing sentence (the systemic side-effect list is credited to [8]). Our copy supports that attribution directly: the Introduction (Section 1) states that chronic GC use is associated with deleterious side effects including glaucoma/cataracts, Section 6 ('Mechanism of steroid-induced secondary ocular hypertension') documents GC-induced IOP elevation occurring within hours, weeks (topical) or years (systemic), and the Conclusion (Section 10) affirms that 'the side effect of increasing intraocular pressure remains a great risk to develop glaucoma'. No contrary statement was found; the other listed effects (abdominal obesity, acne, infection, systemic hypertension) are not attributed to this source, so they do not weaken the verdict. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Interestingly, novel treatments aimed at improving the benefit/risk ratio of GCs therapy (selective GC receptor agonists, SEGRAs), which are currently being trialed, are unlikely to alter the risk of adrenal insufficiency.”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.1. Synthetic Glucocorticoids
What the sources say
- Partly supportedcites [36] Schacke H. Schottelius A. Docke W.D. Strehlke P. Jaroch S. Schmees N. Rehwinkel H. Hennekes H. Asadullah K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects Proc. Natl. Acad. Sci. USA 2004 101 227 232 10.1073/pnas.0300372101 14694204 PMC314167 sourceExperimental — accuracy not yet measured
The Results report that the SEGRA ZK 216348 suppressed ACTH in rats about as effectively as prednisolone. The Discussion says the authors do not expect this compound class to have an advantage over standard glucocorticoids in suppressing the hypothalamo-pituitary-adrenal axis. The paper does not measure adrenal insufficiency risk in patients and says clinical studies are needed to determine whether its findings translate to humans. (LLM, conf=0.84)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This is probably because adrenal insufficiency can develop with the same mechanism, mediating the “therapeutic” anti-inflammatory effects of these compounds [36].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.1. Synthetic Glucocorticoids
What the sources say
- Supportedcites [36] Schacke H. Schottelius A. Docke W.D. Strehlke P. Jaroch S. Schmees N. Rehwinkel H. Hennekes H. Asadullah K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects Proc. Natl. Acad. Sci. USA 2004 101 227 232 10.1073/pnas.0300372101 14694204 PMC314167 source
The Abstract/Introduction of our copy states that 'the antiinflammatory effects are mediated to a major extent via transrepression' while 'a key mechanism for suppression of the hypothalamo-pituitary-adrenal axis, the decreased release of adrenocorticotropic hormone (ACTH) by corticotrophin-releasing hormone, is mediated by the GR via a transrepression mechanism.' The Discussion (and Abstract) confirm this consequence: the SEGRA ZK 216348 retained HPA-axis/ACTH suppression comparable to prednisolone precisely because that side effect shares the transrepression mechanism of the therapeutic effect. The paper phrases the outcome as HPA-axis/ACTH suppression (with adrenal weight reduction as a related measure) rather than 'adrenal insufficiency,' but the mechanism-identity the claim attributes is stated. (LLM, conf=0.85)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mice with a specific GR-deletion in the forebrain show HPA axis hyperactivity; basal cortisol is increased, as well as post-stress cortisol and ACTH levels [57].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.2. Negative Feedback Loop and Glucocorticoid Receptors
What the sources say
- Partly supportedcites [57] Arnett M.G. Muglia L.M. Laryea G. Muglia L.J. Genetic approaches to hypothalamic-pituitary-adrenal axis regulation Neuropsychopharmacology 2016 41 245 260 10.1038/npp.2015.215 26189452 PMC4677126 sourceExperimental — accuracy not yet measured
The “Forebrain GR deletion” section reports HPA-axis hyperactivity and increased basal and post-stress cort and post-stress ACTH in male forebrain-GR-deletion mice. It also says female mice showed no increase in basal or stress-induced cort, so the claim is too broad without the male qualifier. The paper calls the measured hormone “cort,” not cortisol. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moved to clinical practice, this model helps to understand that, in adrenal insufficiency, loss of GC feedback, by itself, can increase POMC gene expression in the pituitary (suggesting that CRH is not absolutely required for changes in POMC expression in response to absolute GC deficiency), but CRH action is essential to guarantee the increase of ACTH secretion.”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.2. Negative Feedback Loop and Glucocorticoid Receptors
What the sources say
- Supportedcites [59] Muglia L.J. Jacobson L. Luedke C. Vogt S.K. Schaefer M.L. Dikkes P. Fukuda S. Sakai Y. Suda T. Majzoub J.A. Corticotropin-releasing hormone links pituitary adrenocorticotropin gene expression and release during adrenal insufficiency J. Clin. Investig. 2000 105 1269 1277 10.1172/JCI5250 10792002 PMC315436 source
The Discussion states that POMC mRNA increased after adrenalectomy in CRH-deficient mice and explicitly concludes that CRH is not absolutely required for changes in POMC expression in response to absolute glucocorticoid deficiency. The Introduction likewise says loss of glucocorticoid feedback can increase pituitary POMC gene expression without CRH. (LLM, conf=0.95)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
146 more claims · 15 with their cited sources checked
Create a free account to see all 211 claims and to verify the 175 references still open.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 52
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is potentially linked to its pharmacokinetics (long half-life of 14.4 hours) and pharmacodynamics (binding affinity to the glucocorticoid receptors 18 times that of dexamethasone) (112).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [112]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.3. Clinical Consequence: Tertiary Hypoadrenalism and Adrenal Crisis
“the risk of suppressed adrenal function after a seven-day prednisone treatment is increased in subjects who have a low cortisol level after a dexamethasone suppression test [84].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > References
“84. Neidert S. Schuetz P. Mueller B. Christ-Crain M. Dexamethasone suppression test predicts later development of an impaired adrenal function after a 14-day course of prednisone in healthy volunteers”
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 2×
“Named for their effect on carbohydrate metabolism, glucocorticoids (GCs) regulate different cellular functions as homeostasis, metabolism, development, cognition, and inflammation [1].”
BackgroundThe Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458 · cited 3×
“StAR protein, in turn, mediates the translocation of cholesterol to the inner mitochondrial membrane, where the first steroidogenic enzyme is located [18].”
BackgroundMechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847 · cited 1×
“Unfortunately, their therapeutic actions are counterbalanced by adverse side effects associated with high doses and long-term use, such as osteoporosis, skin atrophy, diabetes, hypertension, abdominal obesity, acne, infection, and growth retardation [8], as well as ocular hypertension [9].”
BackgroundImmune regulation by glucocorticoids
Cain, D. W., & Cidlowski, J. A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.1 · Cited by 1,846
Regulation of the Hypothalamic‐Pituitary‐Adrenocortical Stress Response
Herman, J. P., McKlveen, J. M., Ghosal, S., Kopp, B., Wulsin, A., Makinson, R., Scheimann, J., & Myers, B. (2016) · Comprehensive Physiology · doi:10.1002/cphy.c150015 · Cited by 1,819
Corticosteroid inhibition of acth secretion
KELLER-WOOD, M. E., & DALLMAN, M. F. (1984) · Endocrine Reviews · doi:10.1210/edrv-5-1-1 · Cited by 1,219
Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol
Van Cauter, E. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.7.2468 · Cited by 951 · cited 1×
“No difference in physiological cortisol secretion is related to weight or gender [21].”
Background11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887 · cited 1×
“MR expression shows a restricted tissue distribution, with high expression in classical aldosterone target organs, such as kidney, colon, salivary glands, and specific brain regions, and more modest expression in heart, vascular tissues, adipocytes, and specific immune cell populations [52].”
BackgroundKarst, H., Berger, S., Turiault, M., Tronche, F., Schütz, G., & Joëls, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507572102 · Cited by 774 · cited 2×
“However, the literature on the mechanism of rapid GC inhibition of HPA activity is confusing: in rats, there is in vivo evidence that this involves a MR-mediated process [63], but ex vivo studies suggest no MR involvement [66].”
BackgroundRamamoorthy, S., & Cidlowski, J. A. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.002 · Cited by 692 · cited 1×
“The discovery that there are multiple GR isoforms generated by alternative splicing [90] leads to understanding the molecular basis for this different sensitivity to GC [91].”
Background
Cited by
Items 101–181 of 181
Liu, X., Jade, N., & Rouhi, O. (2024) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2024.112285 · Cited by 3
RetractedOliveira, J., Torrão, L., Torres-Costa, S., Silva, M. I., Pedrosa, A. C., Araújo, J., Figueira, L., & Oliveira-Ferreira, C. (2025) · Case Reports in Ophthalmology · doi:10.1159/000543908 · Cited by 3
Smith, C. B., Baker, D., Botchu, R., Cairns, M. C., Chester, R., Dean, B. J. F., Mast, R., & Lewis, J. S. (2023) · New Zealand Journal of Physiotherapy · doi:10.15619/nzjp.v51i3.363 · Cited by 4
Prenatal Maternal Stress Suppresses Embryonic Neurogenesis via Elevated Glucocorticoid Levels
Xu, S., Shi, J., Shen, Y., Chen, X., Pourbozorg, G., Wang, G., Yang, X., & Cheng, X. (2024) · Endocrinology · doi:10.1210/endocr/bqae150 · Cited by 6
Effects of Triacetin on AMPK Activation and Immune Responses in Allergic Contact Dermatitis
Yoshimura, Y., & Takahashi, M. (2024) · Allergies · doi:10.3390/allergies4040017 · Cited by 3
“Future studies should further optimize the dose, evaluate the long-term safety, and explore the broader implications of the immunomodulatory effects of TA in other skin conditions.”
Chen, X., Ye, P., Dong, W., Li, Q. C., & Li, T. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2022-003590 · Cited by 3
Roostaei, T., Sabrin, A., Kivisäkk, P., Aubin, C., Nejad, P., Felsky, D., Touil, H., Vlachos, I. S., Hui, D., Fransson, J., et al. (2022) · SSRN Electronic Journal · doi:10.1101/2022.06.29.498195 · Cited by 3
Yadav, M., & Singh, P. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111173 · Cited by 3
Ogun, A. O., Moniruzzaman, M., Jeon, H., Kim, H., Aulia, D., Hur, J., Yoon, S., Lee, S., Min, T., & Lee, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010233 · Cited by 2
“This inhibitory mechanism protects organisms from the detrimental effects of chronic or temperature-induced stress, promoting overall physiological well-being [132].”
Immunomodulatory and Anti-Inflammatory Properties of Glucocorticoids
Ayroldi, E., Migliorati, G., & Riccardi, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00052-9 · Cited by 2
van der Werff, M. H., van der Kamp, H. J., & Breur, J. M. P. J. (2021) · Pediatric Cardiology · doi:10.1007/s00246-021-02704-z · Cited by 2
“25 stronger anti-inflammatory effect than prednisone and a longer biologic half-life, there must be another explanation for the prolonged duration of adrenal insufficiency and the extreme side effects despite supplementation of a maintenance dose of hydrocortisone [15].”
BackgroundGhanem, M. (2021) · Ain-Shams Journal of Anaesthesiology · doi:10.1186/s42077-021-00169-z · Cited by 2
“Sudden cessation of long-term continuous glucocorticoid therapy for more than 3 weeks may result in adrenal insufficiency (Paragliola et al., 2017).”
BackgroundZerillo, L., Polvere, I., Stilo, R., Vito, P., Rinaldi, M., Zotti, T., & Costagliola, C. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.07.010 · Cited by 2
“Last but not least, synthetic GCs are known to elicit different effects on the regulation of the hypothalamic-pituitary axis (HPA) and, as a consequence, of cortisol levels, influencing the systemic response to prolonged GC therapies (Paragliola et al., 2017).”
BackgroundInfluentialMa, B., Shang, T., Huang, J., Tu, Z., Wang, Y., Han, Y., Wang, Y., Wen, X., & Jin, Q. (2022) · Medicine · doi:10.1097/md.0000000000030294 · Cited by 2
“It is most often found in patients with chronic supra-pathological dosages of glucocorticoid analogs,[5] but less frequently with direct”
BackgroundImmune phase transition under steroid treatment
Nayak, S. P., & Roy, S. (2021) · Physical review. E · doi:10.1103/physreve.103.062401 · Cited by 2
Yi, S., Zhao, B., Wei, L., Yao, Z., & Yang, B. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115223 · Cited by 4
Neuroendocrine Theory of Aging
Fernando, H. J., & Bowers, D. (2019) · Springer eBooks · doi:10.1007/978-3-319-69892-2_673-1 · Cited by 2
Neuroendocrine Theory of Aging
Fernando, H. J., & Bowers, D. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_673 · Cited by 3
Treatment and Follow-up of Non-stress Adrenal Insufficiency
Buğrul, F., & Murat, N. Ö. (2024) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.galenos.2024.2024-6-23-s · Cited by 5
“Although these data provide a good population-based estimate of the risk of ICS associated with glucocorticoid use, it is difficult to determine this risk at the individual level (35,36,37,38).”
InfluentialZhou, Y., Zhu, S., Ye, S., Ye, Z., Chen, W., Jiuhao, L. I., Shu, G., Wang, S., Zhu, C., Wu, R., et al. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.12.053 · Cited by 1
Insalaco, A., Vandelli, S., Madeo, S. F., Bruzzi, P., Trevisani, V., Predieri, B., Lucaccioni, L., & Iughetti, L. (2025) · Case Reports in Pediatrics · doi:10.1155/crpe/6109378 · Cited by 1
“While loss-of-function GR polymorphisms are associated with GC resistance, gain-of-function polymorphisms can increase GC sensitivity [7].”
A Novel Mouse Model of the Glucocorticoid Withdrawal Syndrome
Snyder, C. N., Haddad, L. L., Rubin, O., Chang, C.-L., & Spencer-Segal, J. L. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf116 · Cited by 1
“The goal of this model was to administer chronic supra-physiologic doses of glucocorticoid, which is expected to induce HPA axis suppression, as occurs in humans with prolonged endogenous or exogenous glucocorticoid exposure [41].”
Sarkar, S., Abeyagunawardena, A. S., & Sinha, R. (2025) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v14.i4.110374 · Cited by 6
Wang, G., Zhang, X., Duan, G., & Yuan, S. (2026) · Medicine · doi:10.1097/md.0000000000047821 · Cited by 1
Periodontal disease and endocrine imbalance: a molecular pathways perspective
Martínez-García, M., & Lemus, E. H. (2026) · Frontiers in Dental Medicine · doi:10.3389/fdmed.2026.1886028 · Cited by 1
The effects of steroid therapy on the cardiovascular system
Otlewska, A., Szpotowicz, G., & Hackemer, P. (2018) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2018.0028
“These agents may be administered via different routes, e.g. intramuscular, intravenous, oral, inhalation and topical (trans-dermal) (9) .”
Diagnosi e terapia dell’iposurrenalismo secondario a trattamento cronico con steroidi
Simeoli, C., Colao, A., & Pivonello, R. (2019) · L Endocrinologo · doi:10.1007/s40619-018-00512-x · Cited by 1
Mukai, J., Mori, S., Katsumori-Yoshimura, Y., Takeshige, R., Tabata, T., Imada, H., Shimoura, H., Takahashi, H., Takahashi, Y., & Hirata, K. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2502-18 · Cited by 1
“However, considering the wide use of synthetic glucocorticoids, many patients could potentially be at risk of developing adrenal insufficiency particularly after the withdrawal of glucocorticoids (1).”
BackgroundInfluentialSíndrome de Cushing: uma revisão narrativa
Crespo, L. R., Velasco, L. D. A., Peres, D. T., Neto, M. D. L., & Teixeira, A. N. (2021) · Revista Científica da Faculdade de Medicina de Campos · doi:10.29184/1980-7813.rcfmc.495.vol.16.n1.2021 · Cited by 1
Li, D., Li, W., Shi, W., Wu, X., Liu, X., & Gao, P. (2023) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-023-02942-w · Cited by 2
Mechanism of Actions, Efficacy, and Long-term Use of Steroids in Autoimmune Hemolytic Anemia (AIHA)
Yulistiani, Y., Dwiyatna, S., & Utomo, F. N. (2023) · Molecular and Cellular Biomedical Sciences · doi:10.21705/mcbs.v7i3.345 · Cited by 4
Tizianel, I., Ruggiero, E., Torchio, M., Simonato, M., Seresin, C., Bigolin, F., Botta, I. P., Bano, G., Storto, M. L., Scaroni, C. M., et al. (2024) · HORMONES · doi:10.1007/s42000-024-00564-9 · Cited by 2
“However, it is known that patients who have been given systemic long-acting and high-potency GCs are at major risk of developing adrenal insufficiency compared with other conditions due to the GCs’ strong inhibitory effect on the HPA axis [21 ].”
BackgroundLi, J., Li, S., Yang, Y., Deng, Z., Feng, X., Jiang, L., & Wang, J. (2024) · BIO Web of Conferences · doi:10.1051/bioconf/202412402008 · Cited by 1
“…mechanism of the hydrocortisone-induced kidney deficiency model involves using a certain amount of exogenous glucocorticoids to inhibit the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary, thereby reducing the secretion of corticosteroids from the adrenal cortex [11] .”
Acute Adrenal Insufficiency in Childhood: Etiopathogenesis, Clinical Picture, and Intensive Care
Bykov, Y. V., Обедин, А. Н., Фишер, В. В., Volkov, E. V., Yatsuk, I. V., Muravyeva, A. A., & Zinchenko, О. V. (2024) · Ural Medical Journal · doi:10.52420/umj.23.5.125 · Cited by 2
Yuen, K. C. J., Mortensen, M. J., Azadi, A., Fonkem, E., & Findling, J. W. (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.246 · Cited by 1
Zhuikova, S. E. (2021) · Integrative Physiology · doi:10.33910/2687-1270-2021-2-3-279-296 · Cited by 2
“Введение Длительное введение человеку глюкокортикоидов в качестве противовоспалительных и иммунодепрессивных средств вызывает такие негативные эффекты, как повреждение желудочно-кишечного тракта, остеопороз, гипертония, атипичное ожирение (с отложением жира в области лица и шеи), снижение мышечной…”
Hydro-saline Alterations in Central Adrenal Insufficiency
Pivonello, R., Simeoli, C., Paola, N. D., Ferrigno, R., & Colao, A. (2023) · Endocrinology · doi:10.1007/978-3-031-27119-9_7 · Cited by 1
Chouhan, A. S., Parihar, B., Rathod, B., & prajapat, R. (2021) · Research Square · doi:10.21203/rs.3.rs-634590/v1 · Cited by 1
Lefèbvre, H., & Goichot, B. (2018) · Annales d Endocrinologie · doi:10.1016/j.ando.2018.03.009
Serpoi, G., & Cucu, C. (2018) · Medicina Moderna - Modern Medicine · doi:10.31689/rmm.2018.25.2.95
Saini, N. (2018) · Current Trends in Biomedical Engineering & Biosciences · doi:10.19080/ctbeb.2018.17.555951
“Blood levels of GCs are regulated by hypothalamus-pituitaryadrenal (HPA) axis activity [14-16].”
BackgroundIatrogénie et syndromes de Cushing
Ruellan, A., & Boels, D. (2019) · Actualités Pharmaceutiques · doi:10.1016/j.actpha.2019.02.006
CORTICOSTEROIDS - (UN)PREDICTABLE INDUCERS OF PSYCHIATRIC DISORDERS
Telbizova, T., & Arnaoudova, M. (2019) · Journal of IMAB - Annual Proceeding (Scientific Papers) · doi:10.5272/jimab.2019254.2775
Osteoporosis, Glucocorticoid-Related Osteoporosis and Glucocorticoid Withdrawal Regimen
Saiegh, L., & Sheikh‐Ahmad, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-44234-7_8
Effet de la corticothérapie orale au long cours chez les patients asthmatiques sévères de type T2
Ahmed, E., Lahmar, Z. M., Charriot, J., & BOURDIN, A. A. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30729-1 · Cited by 2
Review Article on Hypersensitivity Pneumonitis
Tony, F., Soliman, Y. M. A., & Salem, H. A. (2021) · Azhar International Journal of Pharmaceutical and Medical Sciences/Azhar International Journal of Pharmaceutical and Medical Sciences · doi:10.21608/aijpms.2021.210567
case report on topical steroids causing infantile iatrogenic cushing syndrome
Clince, J., Ravanagomagan, M., Ramesh, S., & Sundari, S. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns2.7242
Insuffisance corticotrope postcortisonothérapie
Chafai, K., Laloi-Michelin, M., & Gautier, J. (2022) · Elsevier eBooks · doi:10.1016/b978-2-294-77859-9.00020-7
(2022) · Journal of Clinical Images and Medical Case Reports · doi:10.52768/2766-7820/2040
Ermakov, A. M., Kudykina, N., Bykova, A., & Tkacheva, U. (2023) · Biology · doi:10.3390/biology12020292 · Cited by 1
“The nature of the interaction of methylprednisolone with receptors may change over time [18].”
Stress as a Determinant of Neurodevelopmental Outcomes
Kim, B., & Matthews, S. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-20792-1_10
Sindrome di Cushing iatrogena e iposurrenalismo terziario
Alessi, Y., Cannavò, S., & Ferraù, F. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01307-5
“La somministrazione di GC esogeni, anche a piccole dosi e/o per un breve periodo (giorni), causa la soppressione dell’asse HPA, sopprimendo la sintesi di POMC, ACTH e altri peptidi derivati da POMC e diminuendo la sintesi e la secrezione di CRH, che risulta essere essenziale per gli eventi post-trascrizionali necessar…”
BackgroundInfluentialHydro-saline Alterations in Central Adrenal Insufficiency
Pivonello, R., Simeoli, C., Paola, N. D., Ferrigno, R., & Colao, A. (2022) · Endocrinology · doi:10.1007/978-3-030-44628-4_7-1
Severe Asthma Patients: Can We Really Wean Them off of Oral Corticosteroids
Pozo-Beltrán, C. F., Elizondo-Villarreal, B., Morett-Vera, F., González-Uribe, V., Rodriguez-Romo, R. M., Navarrete-Rodriguez, E. M., Paniagua-Santos, J. A., Ledezma-Ortega, J. F., & Briceño-Gamboa, A. V. (2023) · Current Treatment Options in Allergy · doi:10.1007/s40521-023-00340-x
“When one administers a CYP3A4 inhibitor simultaneously with a glucocorticoid, the elimination of the last one will be decreased; thus, the efficacy will be augmented, which can lead to serious glucocorticoid excess causing, i.e., iatrogenic Cushing syndrome [18].”
BackgroundOral Glucocorticoid withdrawal and assessment of the hypothalamic-pituitary-adrenal axis
Correia, S., da Silva, J. I. B. S., Rocha, G., & Oliveira, M. (2023) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/ar220048
Diabetes Care in the Oncologic Population
Presswala, L. S., Farooki, A., & Flory, J. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_24
Lattif, F. A., Aziz, D. A., Mohamed, D., & Genedy, G. (2024) · Egyptian Journal of Cell and Tissue Research · doi:10.21608/ejctr.2024.227311.1008
“Furthermore, it lowers quality of life, reduces life expectancy and raises health-care costs (30) .”
BackgroundGlucocorticosteroids – a new target in the treatment of metabolic syndrome
Baumgart, S., Kupczyk, D., & Studzińska, R. (2024) · Farmacja Polska · doi:10.32383/farmpol/186963
“Regulacja wydzielania glukokortykosteroidów odbywa się pod kontrolą osi podwzgórze-przy-sadka-nadnercza (ang. hypothalamo-pituitary--adrenal axis , HPA), na zasadzie podwójnego ujemnego sprzężenia zwrotnego ( rycina 2 ) [15].”
Emerging techniques for manipulating endocrine function in animal production: A comprehensive review
Muzemil, A., & Buhari, A. (2024) · Journal of Istanbul Veterinary Sciences · doi:10.30704/http-www-jivs-net.1426047
“Examples of these complex feedback loops are the hypothalamus - pituitary axis and the pituitary - adrenal axis, which finely tune hormone production and release (Paragliola et al., 2017).”
BackgroundMagcwebeba, T., McEvoy, L., Hayward, S., Tait, T., Quanson, J. L., Kelbe, L., Gelderblom, W., Lilly, M., Swart, A. C., & Swart, P. (2024) · Phytomedicine Plus · doi:10.1016/j.phyplu.2024.100688
¿Son los corticoides inhalados una posible causa de síndrome de Cushing?
Prieto-Álvarez, A., Machín-Lázaro, J. M., Piedra-Castro, R., & Blanco-Crespo, M. (2024) · Revista Española de Casos Clínicos en Medicina Interna · doi:10.32818/reccmi.a9n3a6
Melatonin modulation of the chronic dexamethasone-induced adrenal insufficiency
Mohanty, B., & Mishra, B. K. (2025) · Endocrine · doi:10.1007/s12020-025-04175-1
“…(CRH), adrenocorticotropic hormone (ACTH) from the anterior pituitary, and glucocorticoid (GC) hormones from the adrenal cortex (mainly cortisol in primates and corticosterone/CORT in rodents) plays a major role in the maintenance of metabolic, immune and homeostasis of mental health [1 – 3].”
Wang, X., An, F., Zhao, X., Wang, B., Yan, L., & Han, W. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2487159
“Long-term glucocorticoid therapy may lead to metabolic complications including weight gain, impaired glucose tolerance, and osteoporosis, with the frequency and severity often correlating with cumulative dose and duration of treatment [10].”
Haack, M., & Sethna, N. F. (2025) · Current Sleep Medicine Reports · doi:10.1007/s40675-025-00326-y · Cited by 1
“Corticosteroids are widely prescribed for treating inflammatory diseases, including musculoskeletal and autoimmune diseases, for controlling inflammation and pain [18].”
Steiner, R., & Luginbühl, M. (2025) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001389
“2 5 Beyond its therapeutic applications, dexamethasone has widely been utilized as a diagnostic tool to assess disorders of the hypothalamic – pituitary – adrenal (HPA) axis.”
Finnie, J., Tse, Y., Sampath, S., Alawad, H., Wood, C. L., & Cheetham, T. D. (2025) · Archives of Disease in Childhood · doi:10.1136/archdischild-2025-328917
Management of the interaction between the multiple pituitary hormone deficiencies
Feldt‐Rasmussen, U., Effraimidis, G., Rasmussen, Å. K., & Klose, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00392-7
Karaer, M. C., & Snoj, T. (2026) · Frontiers in Environmental Science · doi:10.3389/fenvs.2026.1761496 · Cited by 2
Mestre, J. L. (2018) · theses.fr (ABES) · doi:10.70675/cab4c4e4z049az4c9czbbefzbf46cdba1d44 · Cited by 1
Glucocorticoid receptor activity in triple negative breast cancer
Noureddine, L. M. (2022) · theses.fr (ABES) · doi:10.70675/13ab50cfz7edbz4a44z918aza657b9614a4d · Cited by 1
Mechanistic links between CSCR and corticoids
Zola, M. (2023) · theses.fr (ABES) · doi:10.70675/3a08e2f8z3b27z4665zb212zbae7666d47d6
Mahmoudi, N. E. (2022) · theses.fr (ABES) · doi:10.70675/68e2ad9bzd00bz4539z8b49z2a120516daca
Turska, E., Lewandowski, K. C., Symonowicz, I., Kobus, M., Horzelski, W., Kubiatowski, T., Marchewka, J., & Kalinka, E. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1810229
Akpan, M. M., Ikeji, C. N., Arije, C. M., Mohammed, K. A., Salaudeen, F. A., Adedara, I., Owumi, S. E., & Farombi, E. O. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2662624
“…stress, and inflammatory factors [10], and is an important target for the prevention and treatment of depression and other stress-related diseases [55]. atrazine-induced activation of the hPa axis is characterized by increased plasma levels of corticotropin-releasing hormone (cRh),…”
Steroid use in glomerular diseases: Friend or foe?
Alghamdi, N. (2025) · Saudi Journal of Internal Medicine · doi:10.4103/sjim.sjim_38_25
Salman, R. A., Kamoona, H. R., Ridha‐Salman, H., & Soussi, A. (2026) · Pharmacia · doi:10.3897/pharmacia.73.e182945
Wu, H. M., Yang, Y., & Deng, Z. P. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07855-3
“Chronic glucocorticoid therapy disrupts HPA axis function, pre-cipitating mood disorders [35].”
Glucocorticoids and placental 11βHSD2 – A systematic review of human studies and animal models
Pfeiffer, P., Alhasan, M. M., Sloboda, D. M., Braun, T., & Entringer, S. (2026) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2026.107988
Architect or Destroyer: The Diversity of Glucocorticoid Receptor Signaling Pathways in the Brain
Shkarina, L. N., Khaybullina, R., Primak, A. L., Дмитриевич, Б. К., Станиславович, Д. С., & Karagyaur, M. N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209027
“A decrease in the level of ACTH, in its turn, leads to a decrease in the endogenous secretion of cortisol or corticosterone by the adrenal cortex [211,212].”
Metadata
- Authors
- Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Corsello, Salvatore Maria
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-10-20
- Volume
- 18
- Issue
- 10
- Pages
- 2201
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5666882
- OpenAlex
- W2765223108
- Semantic Scholar
- ad19ea2188368acba719dc110c72abdf5db33d87
- Cited by
- 181
- References
- 93
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 23 · 2023: 23 · 2022: 25 · 2021: 34 · 2020: 16 · 2019: 23 · 2018: 10 · 2017: 1
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- synthetic glucocorticoids, hypothalamic-pituitary-adrenal axis, Cushing's syndrome, tertiary adrenal insufficiency, corticotropin-releasing factor, ACTH, glucocorticoid withdrawal
- MeSH terms
- Adrenocorticotropic Hormone, Animals, Corticotropin-Releasing Hormone, Cushing Syndrome, Glucocorticoids, Humans, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System, Feedback, Physiological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.